Abstract

DOMINGUEZ, Judith et al. New interaction modalities between the pharmaceutical industry and physicians. Gac. Méd. Méx [online]. 2022, vol.158, n.3, pp.167-169.  Epub Sep 28, 2022. ISSN 2696-1288.  https://doi.org/10.24875/gmm.22000013.

Due to sanitary restrictions secondary to the COVID-19 pandemic, various interactions between the pharmaceutical industry and physicians have changed. One of them has been the method for promoting medicinal products through academic meetings around diseases of financial interest. A recent modality has been unilateral promotion by the pharmaceutical industry through academic events with the invitation of so-called “experts” for the promotion of a specific drug; these meetings are often biased not towards optimal care of a disease, but rather towards commercial promotion of a specific drug, which may or may not be the best option, without considering associated therapeutic alternatives. The Committee of Ethics and Transparency in the Physician-Industry Relationship, of the National Academy of Medicine, analyzes this new circumstance and proposes some considerations to the medical community.

Keywords : Drug promotion; Medical curriculum; Medical meetings; Opinion leader; Pharmaceutical companies.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )